Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: A historical perspective"

Biochemical and Biophysical Research Communications

Volumn 296, Issue 2, 2002, Pages 229-232

  Demuth, Hans Ulrich ^a   Hinke, Simon A ^b   Pederson, Raymond A ^b   McIntosh, Christopher H S ^b  

^a PROBIODRUG AG   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENZYME INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; METFORMIN;

AMINO TERMINAL SEQUENCE; BLOOD CHEMISTRY; DRUG EFFECT; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; REVIEW;

EID: 0036391928     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)00753-2     Document Type: Article

References (47)

1. C.F. Deacon, J.J. Holst, Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective, Biochem. Biophys. Res. Commun. 294 (2002) 1-4.
2. S.A. Hinke, K. Kühn-Wache, T. Hoffmann, R.A. Pederson, C.H.S. McIntosh, H.-U. Demuth, Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like pepide-1, Biochem. Biophys. Res. Commun. 291 (2002) 1302-1308.
3. D.I. Buckley, P. Lundquist, Analysis of the degradation of insulinotropin [GLP-1 (7-37)] in human plasma and production of degradation resistant analogs (abstract), Regul. Pept. 40 (1992) 117.
4. H. Jörnvall, M. Carlquist, S. Kwauk, S.C. Otte, C.H.S. McIntosh, J.C. Brown, V. Mutt, Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP), FEBS Lett. 123 (1981) 205-210.
5. J.C. Brown, M. Dahl, S. Kwauk, C.H.S. McIntosh, S.C. Otte, R.A. Pederson, Actions of GIP, Peptides 2 (Suppl. 2) (1981) 241-245.
6. R.A. Pederson, Gastric inhibitory polypeptide, in: J.H. Walsh, G.J. Dockray (Eds.), Gut Peptides: Biochemistry and Physiology, Raven Press, New York, 1994, pp. 217-259.
7. W.E. Schmidt, E.G. Siegel, H. Kümmel, B. Gallwitz, W. Creutzfeldt, Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39, Endocrinology 120 (1987) 835-837.
8. S.A. Hinke, R.W. Gelling, R.A. Pederson, S. Manhart, C. Nian, H.-U. Demuth, C.H.S. McIntosh, Dipeptidyl peptidase IV-resistant [D-Ala2] glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats, Diabetes 51 (2002) 652-661.
9. R.A. Pederson, T.J. Kieffer, R. Pauly, H. Kofod, J. Kwong, C.H.S. McIntosh, The enteroinsular axis in dipeptidyl peptidase IV-negative rats, Metabolism 45 (1996) 1335-1341.
10. D. Marguet, L. Baggio, T. Kobayashi, A.-M. Bernard, M. Pierres, P.F. Nielsen, U. Ribel, T. Watanabe, D.J. Drucker, N. Wagtmann, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26, Proc. Natl. Acad. Sci. USA 97(2000) 6874-6879.
11. N. Yasuda, T. Nagakura, K. Yamazaki, T. Inoue, I. Tanaka, Improvement of high fat-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats, Life Sci. 71 (2002) 227-238.
12. T. Nagakura, N. Yasuda, K. Yamazaki, H. Ikuta, S. Yoshikawa, O. Asano, I. Tanaka, Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats, Biochem. Biophys. Res. Commun. 284 (2001) 501-506.
13. H.U. Demuth, J. Heins, Catalytic mechanism of dipeptidyl peptidase IV, in: B. Fleischer (Ed.), Dipeptidyl Peptidase IV (CD26) in Metabolism and the Immune Response, R.G. Landes Company, Georgetown, 1995, pp. 1-35.
14. H.-U. Demuth, Recent developments in inhibiting cysteine and serine proteases, J. Enzyme Inhib. 3 (1990) 249-278.
15. E. Schon, I. Born, H.-U. Demuth, J. Faust, K. Neubert, T. Steinmetzer, A. Barth, S. Ansorge, Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes, Biol. Chem. Hoppe-Seyler 372 (1991) 305-311.
16. C.F. Deacon, T.E. Hughes, J.J. Holst, Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptides 1 in the anesthetized pig, Diabetes 47 (1998) 764-769.
17. R. Mentlein, B. Gallwitz, W.E. Schmidt, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum, Eur. J. Biochem. 214 (1993) 829-835.
18. T.J. Kieffer, C.H.S. McIntosh, R.A. Pederson, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology 136 (1995) 3585-3596.
19. C.F. Deacon, M.A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, J.J. Holst, Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects, Diabetes 44 (1995) 1126-1131.
20. C.F. Deacon, A.H. Johnsen, J.J. Holst, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo, J. Clin. Endocrinol. Metab. 80 (1995) 952-957.
21. H. Sjostrom, O. Noren, J. Olsen, Structure and function of aminopeptidase N, Adv. Exp. Med. Biol. 477 (2000) 25-34.
22. A. Sedo, R. Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochem. Biophys. Acta 1550 (2001) 107-116.
23. E. Kominami, K. Ishido, D. Muno, N. Sato, The primary structure and tissue distribution of cathepsin C, Biol. Chem. Hoppe-Seyler 373 (1992) 367-373.
24. A. Yaron, F. Naider, Proline-dependent structural and biological properties of peptides and proteins, Crit. Rev. Biochem. Mol. Biol. 28 (1993) 31-81.
25. S. Wilk, Prolyl endopeptidase, Life Sci. 33 (1983) 2149-2157.
26. K. Hupe-Sodmann, G.P. McGregor, R. Bridenbaugh, R. Göke, B. Göke, H. Thole, B. Zimmermann, K. Voigt, Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1 (7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides, Regul. Pept. 58 (1995) 149-156.
27. K. Hupe-Sodmann, R. Göke, B. Göke, H.H. Thole, B. Zimmermann, K. Voigt, G.P. McGregor, Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells, Peptides 18 (1997) 625-632.
28. C.F. Deacon, M.A. Nauck, J. Meier, K. Hücking, J.J. Holst, Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide, J. Clin. Endocrinol. Metab. 85 (2000) 3575-3581.
29. R.P. Pauly, F. Rosche, M. Wermann, C.H.S. McIntosh, R.A. Pederson, H.-U. Demuth, Investigation of GIP1-42 and GLP-1 7-36 degradation in vitro by dipeptidyl peptidase IV (DPIV) using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectometry (MALDI-TOF MS): a novel kinetic approach, J. Biol. Chem. 271 (1996) 23222-23229.
30. R. Wolf, F. Rosche, T. Hoffmann, H.-U. Demuth, Immunoprecipitation and liquid chromatographic-mass spectrometric determination of the peptide glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 from human plasma samples. New sensitive method to analyse physiological concentrations of peptide hormones, J. Chromatogr. A 926 (2001) 21-27.
31. J.J. Holst, C.F. Deacon, Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes, Diabetes 47 (1998) 1663-1670.
32. C.F. Deacon, L. Pridal, M. Olesen, L. Klarskov, J.J. Holst, Dipeptidyl peptidase inhibition influences GLP-1 metabolism in vivo (abstract), Regul. Pept. 64 (1996) 30.
33. R.P. Pauly, H.-U. Demuth, F. Rosche, J. Schmidt, H.A. White, C.H.S. McIntosh, R.A. Pederson, Inhibition of dipeptidyl peptidase IV (DP IV) in rat results in improved glucose tolerance (abstract), Regul. Pept. 64 (1996) 148.
34. R. Perfetti, T.A. Brown, R. Velikina, S. Busselen, Control of glucose homeostasis by incretin hormones, Diabetes Technol. Therap. 1 (1999) 297-305.
35. H.-C. Fehmann, R. Göke, B. Göke, Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide, Endocrine Rev. 16 (1995) 390-410.
36. W. Creutzfeldt, R. Ebert, New developments in the incretin concept, Diabetologia 28 (1985) 565-573.
37. J.F. Habener, The incretin notation and its relevance to diabetes, Endocrinol. Metab. Clin. North Am. 22 (1993) 775-794.
38. W. Creutzfeldt, The incretin concept today, Diabetologia 16 (1979) 75-85.
39. M. Zander, M. Taskiran, M.-B. Toft-Nielsen, S. Madsbad, J.J. Holst, Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes, Diabetes Care 24 (2001) 720-725.
40. E. Mannucci, A. Ognibene, F. Cremasco, G. Bardini, A. Mencucci, E. Pierazzuoli, S. Ciani, G. Messeri, C.M. Rotella, Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects, Diabetes Care 24 (2001) 489-494.
41. S.A. Hinke, C.H.S. McIntosh, T. Hoffmann, K. Kühn-Wache, L. Wagner, J. Bär, S. Manhart, M. Wermann, R.A. Pederson, H.-U. Demuth, On combination therapy of diabetes with metformin and DP IV inhibitors (letter), Diabetes Care 25 (2002) 1490-1491.
42. W. Creutzfeldt, The entero-insular axis in type 2 diabetes-incretins as therapeutic agents, Exp. Clin. Endocrinol. Diabetes 109 (Suppl. 2) (2001) S288-S303.
43. S. Scharpe, I. De Meester, Peptide truncation by dipeptidyl peptidase IV: a new pathway for drug discovery, Verh. K. Acad. Geneesk. Belg. 63 (2001) 5-32.
44. M. Hildebrandt, W. Reutter, P. Arck, M. Rose, B.F. Klapp, A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence, Clin. Sci. 99 (2000) 93-104.
45. B.B. Zhang, D.E. Moller, New approaches in the treatment of type 2 diabetes, Curr. Opin. Chem. Biol. 4 (2000) 461-467.
46. R. Mentlein, Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides, Regul. Pept. 85 (1999) 9-24.
47. K. Augustyns, G. Bal, G. Thonus, A. Belyaev, X.M. Zhang, W. Bollaert, A.M. Lambier, C. Durinx, F. Goossens, A. Haemers, The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential oB DPP IV inhibitors, Curr. Med. Chem. 6 (1999) 311-327.